bluebird bio (Nasdaq:BLUE) - Cotización, noticias y análisis

Resumen de acción BLUE

bluebird bio, Inc, empresa de biotecnología, investiga, desarrolla y comercializa terapias génicas para enfermedades genéticas graves.

Acerca de la empresa

BLUE fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 40.56%

Los beneficios han crecido un 18.9% al año en los últimos 5 años

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Volatilidad del precio de la acción en los últimos 3 meses

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de bluebird bio, Inc.

Rigel Pharmaceuticals

NasdaqGS:RIGL

US$192.9m

CervoMed

NasdaqCM:CRVO

US$196.6m

2seventy bio

NasdaqGS:TSVT

US$218.7m

Puma Biotechnology

NasdaqGS:PBYI

US$242.2m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for bluebird bio
Historical stock prices
Current Share Price	US$0.92
52 Week High	US$5.53
52 Week Low	US$0.88
Beta	0.80
1 Month Change	-27.86%
3 Month Change	-12.89%
1 Year Change	-78.87%
3 Year Change	-96.88%
5 Year Change	-99.37%
Change since IPO	-96.57%

Noticias y actualizaciones recientes

bluebird bio Is Priced Below IP Value

Mar 23

Bluebird Bio: Innovative Therapies, Monetary Setbacks

Jan 25

Recent updates

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

Aug 17

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Jun 22

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

May 09

Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval

Feb 07

bluebird bio: Ticker Fueled By Gambling Chance Of Commercial Success

Dec 12

bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely

Nov 08

bluebird bio: Like A Bird In The Middle Of The Deep Blue Sea

Nov 03

Rentabilidad de los accionistas

	BLUE	US Biotechs	Mercado US
7D	-3.2%	0.1%	2.2%
1Y	-78.9%	-1.0%	22.8%

Rentabilidad vs. Industria: BLUE obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del -2.3%.

Rentabilidad vs. Mercado: BLUE obtuvo unos resultados inferiores a los del mercado US, que fue del 21.9% el año pasado.

Volatilidad de los precios

Is BLUE's price volatile compared to industry and market?
BLUE volatility
BLUE Average Weekly Movement	15.2%
Biotechs Industry Average Movement	11.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de BLUE ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BLUE(16%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1992	323	Andrew Obenshain	www.bluebirdbio.com

bluebird bio, Inc, empresa de biotecnología, investiga, desarrolla y comercializa terapias génicas para enfermedades genéticas graves. Sus productos candidatos para enfermedades genéticas graves incluyen ZYNTEGLO (betibeglogene autotemcel) para el tratamiento de la ß-talasemia dependiente de transfusión; lovotibeglogene autotemcel para el tratamiento de la anemia falciforme (ECF); y SKYSONA (elivaldogene autotemcel) para tratar la adrenoleucodistrofia cerebral. Los programas de desarrollo clínico de la empresa incluyen HGB-205, HGB-206 y HGB-210 para evaluar la seguridad y eficacia de lovo-cel en el tratamiento de pacientes con ECF; y HGB-204, HGB-205, HGB-207 y HGB-212 para evaluar la seguridad y eficacia de beti-cel en el tratamiento de pacientes con ß-talasemia.

Resumen de fundamentos de bluebird bio, Inc.

¿Cómo se comparan los beneficios e ingresos de bluebird bio con su capitalización de mercado?
Estadísticas fundamentales de BLUE
Capitalización bursátil	US$177.86m
Beneficios(TTM)	-US$91.17m
Ingresos (TTM)	US$21.73m

8.2x

Ratio precio-ventas (PS)

-2.0x

Ratio precio-beneficio (PE)

¿Está BLUE sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BLUE
Ingresos	US$21.73m
Coste de los ingresos	US$255.71m
Beneficio bruto	-US$233.98m
Otros gastos	-US$142.81m
Beneficios	-US$91.17m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.47
Margen bruto	-1,076.97%
Margen de beneficio neto	-419.62%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado BLUE a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BLUE

Recompensas

Análisis de riesgos

Competidores de bluebird bio, Inc.

NasdaqGS:RIGL

US$192.9m

NasdaqCM:CRVO

US$196.6m

NasdaqGS:TSVT

US$218.7m

NasdaqGS:PBYI

US$242.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio Is Priced Below IP Value

Price target increased by 8.0% to US$5.00

Bluebird Bio: Innovative Therapies, Monetary Setbacks

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Recent updates

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio Is Priced Below IP Value

Price target increased by 8.0% to US$5.00

Bluebird Bio: Innovative Therapies, Monetary Setbacks

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Consensus revenue estimates fall by 13%

Price target decreased by 8.2% to US$6.61

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 31% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

Now 24% undervalued after recent price drop

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

Consensus revenue estimates decrease by 26%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Consensus forecasts updated

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Bluebird bio names interim finance chief

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

Bluebird bio jumps 17% on FDA approval of new gene therapy

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

bluebird bio' chief strategy and financial officer to depart

Treasurer recently sold US$78k worth of stock

Consensus forecasts updated

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

President recently sold US$96k worth of stock

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased to US$8.22

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

Chief Regulatory Officer recently sold US$6.7k worth of stock

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Consensus forecasts updated

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential